AU
UK
CA
NZ
IND
US
Last update at 2026-06-03T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
Thu 01 May 25, 02:01 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -7.58200M | -43.38900M | -47.41300M | -56.67200M | -45.43600M |
| Minority interest | - | - | - | - | - |
| Net income | -7.58200M | -43.38900M | -47.41300M | -60.32400M | -50.64000M |
| Selling general administrative | 14.05M | 16.79M | 18.65M | 19.65M | 17.30M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 9.40M | 10.81M | 10.02M | 9.90M | 10.12M |
| Reconciled depreciation | 0.17M | 0.20M | 0.28M | 0.23M | 0.16M |
| Ebit | -32.90200M | -42.77400M | -48.33200M | -53.25300M | -42.06500M |
| Ebitda | -32.73300M | -42.57100M | -48.33200M | -53.02000M | -40.96400M |
| Depreciation and amortization | 0.17M | 0.20M | 0.26M | 0.23M | 1.10M |
| Non operating income net other | - | - | - | -3.65200M | -3.37100M |
| Operating income | -32.90200M | -44.54200M | -48.33200M | -53.02000M | -42.06500M |
| Other operating expenses | 42.34M | 55.45M | 58.35M | 63.18M | 52.71M |
| Interest expense | 2.19M | 0.61M | 2.02M | 4.77M | 4.47M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.32M | 1.77M | 2.81M | 1.12M | 0.21M |
| Net interest income | -1.86900M | 1.15M | -1.95600M | -3.65200M | -4.26100M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | 0.26M | 0.53M |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | -0.25500M | 3.65M | 5.20M |
| Total revenue | 9.44M | 10.91M | 10.02M | 10.16M | 10.65M |
| Total operating expenses | 42.34M | 55.35M | 58.35M | 62.92M | 52.18M |
| Cost of revenue | 0.04M | 0.10M | 0.23M | 0.26M | 0.53M |
| Total other income expense net | 25.32M | 1.15M | 0.92M | -3.65200M | -3.37100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -7.58200M | -43.38900M | -47.03000M | -56.67200M | -45.43600M |
| Net income applicable to common shares | - | - | - | -56.67200M | -45.43600M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 19.97M | 41.27M | 77.28M | 108.85M | 162.30M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.85M | 3.04M | 1.78M | 3.52M | 3.27M |
| Total liab | 14.50M | 47.26M | 57.61M | 62.30M | 71.59M |
| Total stockholder equity | 5.46M | -5.99800M | 19.67M | 46.55M | 90.71M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | 14.67M | 9.04M | 5.68M | 6.34M |
| Common stock | 0.13M | 0.09M | 0.06M | 0.97M | 0.92M |
| Capital stock | 0.13M | 0.09M | 0.06M | 0.97M | 0.92M |
| Retained earnings | -1247.38100M | -1239.79900M | -1196.41000M | -1148.99700M | -1092.32500M |
| Other liab | - | - | - | 49.48M | 53.80M |
| Good will | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M |
| Other assets | 2.35M | - | - | 2.66M | 0.73M |
| Cash | 5.06M | 20.00M | 26.68M | 19.66M | 40.01M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 14.08M | 19.03M | 13.52M | 12.81M | 17.80M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -3.44300M | -17.04300M | -23.88700M | -12.91700M | -34.97400M |
| Short term debt | 1.19M | 1.34M | 1.30M | 3.94M | 5.04M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1.62M | 2.95M | 2.79M | 6.74M | 5.04M |
| Other stockholder equity | 1252.71M | 1233.72M | 1215.79M | 1194.77M | 1182.22M |
| Property plant equipment | - | - | - | 0.69M | 0.51M |
| Total current assets | 5.06M | 26.39M | 60.91M | 89.23M | 143.80M |
| Long term investments | - | - | - | 0.00000M | 23.96M |
| Net tangible assets | - | - | - | 37.57M | 81.72M |
| Short term investments | - | 0.00000M | 29.65M | 65.97M | 75.87M |
| Net receivables | 0.00000M | 3.35M | 2.79M | 2.98M | 3.22M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | -2.88600M | -2.54100M |
| Accounts payable | 12.89M | 3.02M | 3.17M | 3.19M | 6.42M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | 0.23M | -0.18600M | -0.10900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.97M | 0.92M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -1148.99700M | -1092.32500M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -0.54400M | 1.96M | 2.52M | 5.54M | 3.27M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 12.55M | 14.88M | 16.37M | 19.61M | 18.50M |
| Capital lease obligations | 1.62M | 2.95M | 2.79M | 3.94M | 5.04M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00000M | 29.44M | 26.73M | 33.44M | -47.89500M |
| Change to liabilities | - | - | - | -3.88400M | 4.96M |
| Total cashflows from investing activities | 2.50M | 29.44M | 37.79M | 33.02M | -47.89500M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 9.77M | 3.44M | 7.58M | 0.87M | -4.17200M |
| Change to operating activities | - | - | - | -3.18300M | -3.78000M |
| Net income | -7.58200M | -43.38900M | -47.41300M | -56.67200M | -45.43600M |
| Change in cash | -14.93600M | -6.68400M | 6.93M | -20.44700M | -89.68600M |
| Begin period cash flow | 20.54M | 27.23M | 20.29M | 40.74M | 130.43M |
| End period cash flow | 5.61M | 20.54M | 27.23M | 20.29M | 40.74M |
| Total cash from operating activities | -27.20100M | -39.56300M | -38.43400M | -54.33700M | -37.61900M |
| Issuance of capital stock | 15.35M | 12.02M | 13.74M | 5.59M | 0.00000M |
| Depreciation | 0.17M | 0.19M | 0.26M | 0.23M | 0.16M |
| Other cashflows from investing activities | 2.50M | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -1.03200M | -0.55500M | 0.18M | 0.25M | -0.18100M |
| Sale purchase of stock | - | - | - | 5.84M | 0.30M |
| Other cashflows from financing activities | 9.77M | -8.58600M | -6.53700M | -4.72700M | -4.47200M |
| Change to netincome | - | - | - | 2.33M | 7.82M |
| Capital expenditures | 0.00000M | 0.00000M | 0.42M | 0.42M | 0.42M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -20.44700M | -89.68600M |
| Change in working capital | 1.75M | -3.71600M | 2.78M | -6.81800M | 1.00M |
| Stock based compensation | 4.02M | 5.93M | 6.00M | 6.75M | 5.28M |
| Other non cash items | -25.55600M | 1.43M | -0.05500M | 2.17M | -0.02600M |
| Free cash flow | -27.20100M | -39.56300M | -38.43400M | -54.75300M | -37.61900M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRIS Curis Inc |
-0.0025 0.50% | 0.50 | - | - | 2.54 | 4.49 | 2.23 | 0.56 |
| NVO Novo Nordisk A/S |
-0.92 2.14% | 42.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.75 1.73% | 42.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.25 0.76% | 428.34 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
16.03 2.66% | 618.95 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Building C, Lexington, MA, United States, 02421
| Name | Title | Year Born |
|---|---|---|
| Mr. James E. Dentzer | Pres, CEO & Director | 1967 |
| Dr. Robert E. Martell M.D., Ph.D. | Head of R&D | 1963 |
| Ms. Diantha Duvall CPA, M.B.A. | CFO, Treasurer, Assistant Sec., Principal Financial Officer & Principal Accounting Officer | 1972 |
| Mr. Mark W. Noel | VP of Technology Management & Intellectual Property | 1959 |
| Ms. Elif McDonald | VP of Investor Relations & Corp. Communications | NA |
| Dr. Reinhard Wilhelm von Roemeling M.D. | Sr. VP of Clinical Devel. | NA |
| Mr. James E. Dentzer | President, CEO, Secretary, Treasurer & Director | 1967 |
| Ms. Diantha Duvall C.P.A., M.B.A. | CFO and Principal Financial & Accounting Officer | 1972 |
| Mr. Mark W. Noel | Vice President of Technology Management & Intellectual Property | 1959 |
| Ms. Elif McDonald | VP of Investor Relations & Corporate Communications | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...